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Active immune prevention  
of Streptococcus pneumoniae:  
the milestones
The first attempts for developing a vaccine against Strep-
tococcus pneumoniae (Sp) date from the beginning of 
20th century, with the pioneering studies investigating 
the whole cell preparations. Subsequent investigations 
focused on live attenuated formulations and further stud-
ies led to the preparation of multivalent vaccines, con-
taining partially purified capsular material, in the mid 
’30s. The first generation of polysaccharide vaccines 
became available in the late ’40s. 
The second generation of non-conjugated polysaccharide 
vaccines dates from the late ’70s: a 14-valent vaccine was 
registered in the United States of America (US) in 1977, 
followed by a 23-valent formulation (PPV23) in 1983: 
even with some intrinsic immunological limitations, re-
sulting in suboptimal efficacy to protect against Invasive 
Pneumococcal Diseases (IPD) and non-IPD, PPV23 has 
been targeted for adults belonging to some selected high 
risk categories and elderly, till today, and has been widely 
used worldwide, with million doses distributed. 
To remedy these shortcomings, researchers have focused 
on the development of new types of vaccines against Sp: 
in particular, the formulations conjugating the superficial 
polysaccharide of the bacterium with specific carrier-pro-
teins have undoubtedly marked a revolution in the active 
immune prevention of Sp-related diseases. The rational 
for this strategy lies in the ability of the carrier-protein 
to effectively stimulate the CD4+ T-cell dependent im-
mune response, thus resulting in an optimal stimulation 
of the humoral immunity arm, the creation of a long term 
immunological memory against the presented antigens, 
and the secretion of specific mucosal IgA at the sites of 
entry of the bacterium into the organism [1, 2]. 
The first heptavalent Pneumococcal Conjugate Vaccine 
(PCV7) was licensed in the US in 2000, becoming avail-
able in Europe during the following year: it has been 
distributed in more than 70 Countries, with over 100 
million of doses administered. This vaccine contains the 
polysaccharide antigens of the 7 serotypes (4, 6B, 9V, 
14, 18C, 19F, 23F) responsible, in the pediatric setting, 
for more than 85% of the IPD in the US and for nearly 
75% in Europe during the late ’90s [2]. In the manu-
facturing of this vaccine, each polysaccharide antigen 
is conjugated with a carrier protein, named CRM197, a 
non-toxic mutant obtained from the purification of the 
toxin produced by the Corynebacterium diphtheriae. 
As reported below in more details, PCV7 has been tar-
geted for immunizing infants and children aged < 5 
years, showing significant results against IPD in terms 
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Summary
The wide use of the 7-valent Pneumococcal Conjugate Vaccine 
(PCV7) determined, during the last decade, a dramatic decline 
in the incidence of Invasive Pneumococcal Diseases (IPD) in 
infants and children, and also among the non-vaccinated popu-
lation through the phenomenon known as “herd protection”. 
Furthermore a significant reduction of some non-IPD, such as 
Community Acquired Pneumonia (CAP) and Acute Otitis Media 
(AOM) was reported among the pediatric population. At the same 
time, the high vaccination coverage rates reached with PCV7 
contributed to modify the ecology of Streptococcus pneumoniae 
(Sp), favoring the emergence of some serotypes not included in 
PCV7 and involved in IPD (replacement phenomenon), thus par-
tially affecting the positive effects of the pediatric immunization 
programs. To remedy these shortcomings, a new generation of 
conjugate vaccines, with an enlarged antigenic spectrum of activ-
ity than PCV7, has been available since 2010. In particular, the 
13-valent Pneumococcal Conjugate Vaccine (PCV13) has been 
authorized for active prevention of IPD, CAP and AOM in infants 
and children aged between 6 months and 5 years. More recently, 
in September 2011, the European Medicine Agency extended the 
indication for its use to include active immunization of adults 
aged ≥ 50 years for the prevention of IPD, thus opening new 
interesting opportunities to improve the control of pneumococcal 
disease among the entire population. The most interesting results 
from clinical trials using PCV13 in both children and adults are 
reported and discussed in details.
The full article is free available on www.jpmh.org
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of both efficacy and effectiveness. A further effect has 
been the significant reduction of the IPD even within the 
non-immunized individuals of all age-groups, an indi-
rect phenomenon due to the relevant decline in the circu-
lation of the microorganism in the community (herd ef-
fect). Moreover, an important reduction in the antibiotic 
resistance pattern has been documented following the 
wide clinical use of this vaccine in the pediatric age [2]. 
At the same time, numerous evidences have demon-
strated the substantial impact of the PCV7 also against 
Community Acquired Pneumonia (CAP) and acute otitis 
media (AOM), two of the most relevant clinical pictures 
sustained by Sp [3-8]. 
Associated with the rapid and dramatic decline in the 
prevalence of the IPD caused by vaccine serotypes, the 
pneumococcal vaccination programs affected substan-
tially the ecology of Sp. With respect to this, several 
reports showed an increase in the absolute frequency of 
IPD sustained by non-vaccine pneumococcal serotypes 
just in those Countries that adopted universal childhood 
immunization programs with PCV7. This phenomenon 
is known serotype replacement and has been involving 
numerous serotypes, such as 1, 3, 5, 6A, 7F, 15A, 22F, 
33F, 35B, even if most of the evidences indicate that 
19A serotype undoubtedly plays a major role world-
wide [9-12].
As a matter of fact, a number of research projects has 
been carried out in order to develop new vaccines fur-
ther improving the active immunoprophylaxis against 
the infections sustained by Sp. These efforts resulted in 
a new generation of conjugate vaccines, with enlarged 
antigenic spectrum of activity than the PCV7, available 
since 2010: a 10-valent vaccine (1, 4, 5, 6B, 7F, 9V, 14, 
18C, 19F, 23F), conjugated to protein D of H. influenzae 
and diphtheria and tetanus toxoids, (Synflorix®, GSK, 
Belgium), and a 13-valent CRM197-conjugated vaccine 
(1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F), 
(Prevenar®, Wyeth, US). This latter has been initially 
targeted for the pediatric age, being its use possible also 
for the adults aged > 50 years since 2011.
For a more distant future, several experimental prepara-
tions are still under clinical development, and their prompt 
availability is not currently expected, at least in a short 
and medium term: mucosal-administered and, particular-
ly, proteic vaccines, whose composition is based on spe-
cific Sp proteins, such as pneumolysin, choline binding 
proteins (PspA, PspC and Lyt A) and lipoproteins (PsaA), 
are at an early stage of development [13-15].
Direct and indirect effects  
of the universal children pneumococcal 
immunization programs with the PCV7
PCV7 was adopted in the US since 2000 for routine im-
munization of infants and young children and for older 
children at high-risk for developing IPD. The benefits of 
the introduction of the vaccine into the clinical use were 
substantial and almost immediate in the target pediatric 
population: according to data from the Active Bacterial 
Core Surveillance (ABCs), an active population- and 
laboratory-based surveillance system, the largest decline 
in the incidence rates by age class was recorded among 
children aged one year (-80%), a population showing the 
highest rates of morbidity prior to the vaccine licensure 
and its wide use [16].
Further data from the same national surveillance sys-
tem, comparing the pre-vaccination (1998-1999) ver-
sus the post-vaccination era (2007), have confirmed the 
substantial decline in the incidence rate of IPD among 
the general population, with updated results showing a 
decline of 45% and 94% for cases sustained by all Sp-
types and vaccine types, respectively [12, 17]. Particu-
larly, monitoring a sample of the population of nearly 
1.26 million subjects, a 100% and a 76% reduction in 
IPD rates, related to vaccine serotypes and by all Sp-
types, were registered among children aged less than 5 
years, comparing pre- versus post-vaccination periods, 
with values declining from 81.9/105 to 0.4/105 and from 
98.7/105 to 23.6/105, respectively [12, 17]. Interestingly, 
the universal vaccination of newborns immediately de-
termined an indirect protection against IPD also among 
the non-vaccinated population, a phenomenon, known 
as “herd effect”, already described for other infectious 
diseases: notably, in 2003, the vaccine prevented more 
than twice as many IPD cases in the US, just through this 
indirect effect [16]. This positive effect persisted during 
the years following the introduction of the universal im-
munization program, and resulted particularly marked in 
subjects aged ≥ 65 years, a group at higher risk for IPD 
than the young adult population: comparing average data 
collected in 1998-1999 (baseline) with those in 2007, a 
reduction in IPD rates of 37% and 92% was reported for 
all Sp-types and vaccine types, respectively [12]. This 
phenomenon was attributable to a reduced circulation of 
the Sp within the community, due to the reduction of 
the oropharyngeal carriage of the pathogen within the 
immunized population: this epidemiological scenario 
has been largely described in several studies published 
in the literature, being particularly marked in subjects 
aged > 50 years [16, 18-23].
The wide use of the PCV7 also determined important 
implications on the antibiotic resistance pattern of the 
most prevalent Sp serotypes circulating within the US 
community: the serotypes included in the vaccine formu-
lation were just those most highly resistant to the differ-
ent classes of antibiotics. A 81% reduction in the rate of 
IPD caused by penicillin-non-susceptible serotypes and 
a greater decline by 85% of IPD caused by macrolide-re-
sistant serotypes were registered in US children aged < 2 
years, following the wide introduction of pneumococ-
cal vaccination [24-26]. As a further consequence of the 
herd effect, a parallel decrease of antibiotic resistance 
occurred even in older children and among elderly [24].
Similar results concerning the effects of the PCV7 
against IPD have been also described outside the US, 
thus further confirming the positive effects of the uni-
versal children immunization campaign.
In Canada, where PCV7 has been recommended for rou-
tine vaccination since 2002, a broad active surveillance, 
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conducted among children aged 16 years and younger, 
by 12 centers of the Canadian Immunization Monitor-
ing Program demonstrated that, during the period 2000-
2007, the absolute number of reported IPD cases de-
creased 48% (p < 0.01) over the 8-year period and 56% 
(p < 0.01) in children 0-4 years of age, with a 87.5% 
(p < 0.01) and 92% (p < 0.01) reduction of IPD cases 
sustained by vaccinal serotypes, reported overall and in 
children 0-4 years, respectively [27].
Favorable findings have been registered also in the Euro-
pean Countries which adopted a universal strategy with 
PCV7, according to different immunization schedules, 
either with three (i.e., a 2+1 simplified doses regimen) 
or four doses given to children during the first two years 
of life: for example, an effectiveness of 72% and 74% 
against IPD was reported among the target population 
in England and Wales [28] and in Norway [29], respec-
tively. 
Similarly, a significant reduction in the incidence of IPD 
has also been recently demonstrated in France, where 
PCV7 has been introduced in the national immunization 
schedule since 2003: cases of meningitis and sepsis in 
children aged < 2 years decreased from 9.3/100,000 to 
5.4/100,000 and from 22.4/100,000 to 16.6/100,000, re-
spectively [30]. In the same Country, a 82% reduction in 
the incidence of pneumococcal meningitis in 0-24 month 
children, from 8.9 cases per 100,000 population in 2001 
to 1.8 cases per 100,000 population in 2005 (p = 0.03), 
was documented by others [31].
The first report of the effectiveness of PCV7 in Denmark, 
where a 2+1 schedule was adopted demonstrated that, 1 
year following its introduction in the national childhood 
immunization program, the overall incidence of IPD, 
overall and by vaccine-serotypes, rapidly declined from 
54 to 23 cases per 100,000 and from 36.7 to 7.7 cases per 
100,000 in children aged < 2 years, respectively [32].
In Italy, PCV7 became available in October 2001: the 
Ministry of Health initially recommended the free of 
charge offer of the vaccine only for children affected 
by specific risk conditions (sickle cell anemia, tha-
lassemia, asplenia, etc.), aged < 5 years [33]. Liguria 
was the first Italian administrative Region, since 2003, 
to actively recommend the free of charge immunization 
of all infants with the PCV-7, within a research pilot-
project. Vaccination coverages among infants rapidly 
increased from 42.8% in 2003 to 83.3% in 2004, pro-
gressively reaching levels of 93.4% in 2007. A scientific 
project, aimed at evaluating the effect of the vaccina-
tion campaign, showed, during the period 2000-2007, 
a significant decline in hospitalization rates, among 
children aged 0-24 months, for all-cause and pneumo-
coccal pneumonia (p < 0.05) and for acute otitis media 
(p < 0.01), with preventive fractions of 15%, 70.5% and 
36.4%, respectively [8]. These results clearly showed 
the effectiveness of PCV-7 in the prevention of these 
mucosal non-invasive pneumococcal diseases and are 
broadly in line with other on-field studies performed on 
larger study population.
Of particular interest, with respect to CAP, data from the 
US Nationwide Inpatient survey system reported a 39% 
reduction in hospital admissions for all-cause pneumo-
nia in children aged < 2 years, and of 75% of pneumonia 
with Sp as etiological agent: this resulted in fewer 41,000 
admissions than the expected in the year 2004 [3]. These 
data are superimposable with those reported in a recent 
survey, among children aged < 2 years, showing that the 
rate for all-cause pneumonia was approximately 35% 
lower in 2006 than during the control period 1997-1999, 
with the values of 9.1 per 1,000 and 8.1 per 1,000, in 
the period 2005-2006, respectively [4]. Another Ameri-
can study, comparing the pre-vaccination (1998-1999) 
and the post-vaccination period (2004), demonstrated a 
reduction of 52.4% and of 41.1% in the number of hos-
pitalizations for all-cause pneumonia and of ambulatory 
visits for the same cause, respectively [5].
Similarly, after the PCV7 introduction, also the US 
national rates for AOM outpatient visits significantly 
declined by 20% in children aged < 2 years [6]. Other 
authors described a 42.7% decrease in the number of 
outpatient visits for the same clinical outcome in the 
same target population [7]. Notably, the reduction in the 
incidence of AOM resulted in the consequent decline of 
related surgery interventions, like pressure-equalizing 
tube insertions, confirming the relevant morbidity of 
this microorganism [34]. This is consistent with the fact 
that pneumococcal AOM may present with more severe 
clinical signs and symptoms than AOM caused by either 
H. influenzae and M. catharralis [35]. Moreover, these 
data are well within the range of vaccine-efficacy (10-
50%) demonstrated by the long-term follow up of the 
Finnish Otitis Media (FinOM) and Northern California 
Kaiser Permanente (NCKP) clinical trials against recur-
rent episodes or for the prevention of tympanostomy 
tube placement [36].
Rational for the introduction of 13-valent 
pneumococcal vaccine: the serotype 
replacement 
Before introduction of PCV7, pneumococcal serotypes 
contained in the vaccine were responsible for nearly 
80% of IPD in the US, 70% of the IPD in Europe, and 
40-80% in other Regions of the world [2]. Although the 
dramatic impact, in terms of reduction in both the inci-
dence of IPD and non-IPD, determined by the wide use 
of PCV7, the potential for vaccination to contribute to 
the emergence of serotypes not included in the vaccine, 
the so-called “replacement” phenomenon, thus reducing 
the positive effect of vaccination, has been a concern for 
researchers. Following the introduction of PCV7, sev-
eral studies have identified some non-PCV7 serotypes 
causing IPDs (i.e., 1, 3, 5, 6A, 7F, 15A, 19A, 22F, 33F, 
35B) as emerging serotypes; some of them have shown a 
significant increase, with 19A being the most prevalent. 
Data from ABCs indicated that the overall incidence 
of IPD among children aged < 5 years decreased from 
approximately 99 cases per 100,000 subjects during 
1998-1999 to 21 cases per 100,000 in 2008 (percentage 
reduction: 79%). The reduction in overall IPD resulted 
the 13-valeNt pNeumOCOCCal CONJugate vaCCiNe
71
from a 99% decrease in disease caused by the seven 
serotypes contained in PCV7 and serotype 6A, a sero-
type against which PCV7 provided cross-protection, but 
these decreases have been partially offset by increases 
in IPD caused by non-vaccine serotypes, in particular 
19A [37].
Interestingly, a 15-year prospective surveillance study 
of all culture-proven invasive infections determined by 
Sp in infants and children, hospitalized in 8 children’s 
hospitals in the US, demonstrated that, since the imple-
mentation of routine PCV7 immunization in 2000, IPD 
have decreased yearly from 2001 through 2004. The rate 
of IPD then increased from 2005 through 2008, prima-
rily as a result of serotype 19A isolates. Notably, in 2007 
and 2008, only 16 isolates (4%) were vaccine serotypes, 
while 19A accounted for 46% of the non-PCV7 sero-
types and serotypes 1, 3, and 7F accounted for further 
22% of the non-PCV7 serotypes. Overall, compared 
with the total number of annual admissions, the number 
of 19A isolates increased significantly from 2001 to 
2008 (P < 0.00001) [38]. Further results, obtained from 
30,032 cases laboratory-confirmed IPD cases, including 
5410 among children aged < 5 years, identified in US 
during 1998-2007 period by 8 active population-based 
surveillance sites adhering to ABCs, confirmed this 
trend among general population. In 2006-2007, PCV7 
serotypes accounted for only 2% of all IPD among chil-
dren aged < 5 years, compared with 83% at baseline. The 
proportions of IPD cases caused by PCV7-type strains 
decreased from 56% to 10% and from 56% to 9% among 
18-64-year-old and ≥ 65-year-old adults, respectively. 
Overall and PCV7-type IPD incidence declined by 45% 
(from 24.4 to 13.5 cases per 100,000 population) and 
94% (from 15.5 to 1.0 cases per 100,000 population), 
respectively (P < 0.01). By contrast, the incidence of 
IPD caused by serotype 19A and other non-PCV7 types 
increased from 0.8 to 2.7 cases per 100,000 individu-
als and from 6.1 to 7.9 cases per 100,000 individuals, 
respectively (P < 0.01) [12].
Similar findings have been obtained for pneumococ-
cal meningitis. An active population-based surveillance 
from eight sites in the US, investigating the changes in 
the incidence of pneumococcal meningitis from 1998 
through 2005, demonstrated that the rates of pneumo-
coccal meningitis have decreased among children and 
adults since PCV7 was introduced, but the increase in 
meningitis caused by non-PCV7 serotypes partially re-
duced this result. In more details, overall incidence of 
pneumococcal meningitis declined from 1.13 cases to 
0.79 case per 100,000 persons between 1998-1999 and 
2004-2005 (a 30.1% decline, P < 0.001), and rates of 
PCV7-serotype meningitis declined from 0.66 case to 
0.18 case per 100,000 individuals (a 73.3% decline, 
P < 0.001) among patients of all ages. However the re-
duction of meningitis incidence caused by PCV7-relat-
ed-serotype was less marked (32.1%, P = 0.08), while 
the rates of non-PCV7-serotype disease even increased 
from 0.32 to 0.51 per 100,000 persons (an increase of 
60.5%, P <0 .001), with the most important growth in-
volving serotypes 19A, 22F, and 35B [11].
The emergence of non-PCV7 serotypes, in particular 
19A, has been recently described also in Europe. The 
results of typization of 282 Sp, isolated in 2007 from 
adults and children affected by IPD in France, showed 
that serotype 19A was the most frequently isolated se-
rotype both in children and adults. In particular, 19A 
represented 13.0% and 28.6% of the strains isolated 
from IPD in adults and children, respectively. In this lat-
ter population, the most frequent serotypes isolated in 
IPD, following 19A, were 1 and 3 in 19.0% and 9.0% of 
the cases, respectively. In adults, Sp serotypes involved 
in IPD were more heterogeneous than in children: the 
four most prevalent serotypes representing, together 
with 19A, 50% of the isolated strains were 9 (11.0%), 3 
(9.6%), 7F (8.2%), and 14 (8.2%) [39].
Also in Norway, 19A has been identified as a major cause 
of IPD following the introduction of PCV7. From 2004-
2005 to 2008, even if the incidence rate of IPD in general 
population decreased from 24.05 cases/100,000 popula-
tion in 2004-2005 to 18.09 cases/100,000 population in 
2008, IPD caused by serotype 19A increased from 0.26 to 
0.70 cases/100,000 population. Differently from the US, 
where serotype 19A has also emerged as the most frequent 
cause of drug-resistant IPD, the clinical forms caused by 
penicillin non-susceptible pneumococci (PNSP) serotype 
19A has remained unchanged in Norway; moreover the 
proportion of PNSP serotype 19A among all 19A sero-
types decreased from 2004-2005 to 2008, but this change 
was non statistically significant [40].
With respect to bacteremic pneumonia, an observation-
al study, performed in Italy from April 2007 through 
June 2009, among 292 children aged 0-16 years admit-
ted with a diagnosis of CAP to 83 pediatric hospitals 
in Italy, identified Sp in 80 of 292 patients. Serotype 1 
resulted the most frequent serotype (32.5%) and was sig-
nificantly associated with complications and older age, 
serotype 19A was second in frequency (15.0%) and was 
significantly associated with younger age; serotype 3 
was isolated in 12.5% of the cases [41].
In Liguria, after PCV7 implementation since 2003, the 
global proportion of PCV7 serotype out of all Sp respon-
sible for IPD declined from 38% in 2006-08 to 10% in 
2009-10, compared to the proportion of 51% reported 
by a nationwide surveillance performed before the intro-
duction of the conjugate vaccine. Among non-PCV7 se-
rotypes, the proportion of type 1, 7F and 19A increased 
in the period 2006-2010, although no type reached a pro-
portion higher than 15%. In the post-vaccination period, 
the role of type 3, 6C and 19A has been important also 
among serotypes that cause non-IPD, with proportions 
ranging between 7 and 15% [42].
The introduction of PCV7 vaccination in Liguria has 
also affected the nasopharyngeal carriage of Sp. A 
cross-sectional study, performed collecting nasopharyn-
geal swab from 699 children aged < 5 years, reported 
that among PCV7 serotypes, serotype 4 was carried by 
8.2% (age-weighted carriage prevalence, 95% Confi-
dence Interval – 95%IC = 4.3-12.1%) of the population 
and accounted for 72.2% of all PCV7 isolates. Among 
non-PCV7 serotypes, 5 and 19A showed a higher preva-
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lence, being carried by 15.2% (95%CI = 10.1-20.3%) 
and 8.8% (95%CI = 4.8-12.8%) of the population, re-
spectively [43].
Overview of the 13-valent pneumococcal 
conjugate vaccine phase 3 clinical 
development and introduction of the 13-
valent pneumococcal conjugate vaccine 
in the national childhood vaccination 
schedules 
To address the replacement phenomenon, a 13-valent 
pneumococcal conjugate vaccine (PCV13) has been de-
veloped in order to improve the protection against pneu-
mococcal disease. Actually, according to the known 
serotype prevalence, 90% or more of the invasive pneu-
mococcal disease in most regions of the world should be 
preventable with the use of PCV13 vaccine. However, 
on the basis of guidelines by the World Health Organiza-
tion (WHO) and the requirements of national regulatory 
authorities, the licensing of new pneumococcal vaccines 
required randomized clinical trials to demonstrate the 
non-inferiority of PCV13 compared to existing pneumo-
coccal conjugate vaccines.
Details about the clinical development plan of PCV 13 
are outlined in Tab. I. In particular, since in many coun-
tries PCV7 was administered concomitantly with other 
infant vaccinations, including diphtheria-tetanus-acellu-
lar pertussis-hepatitis B-inactivated polio-Haemophilus 
influenzae type B (DTaP-HBV-IPV/Hib) vaccine, it 
was necessary to demonstrate that the administration of 
PCV13, concomitantly with the other routine infant vac-
cines, was safe, well tolerated and did not interfere with 
the immune response against the concomitant vaccine 
antigens. 
A phase III clinical trial was performed in Italy to com-
pare the safety and immunogenicity of PCV13 with 
those of PCV7 when administered concomitantly with 
DTaP-HBV-IPV/Hib vaccine. 606 infants were en-
rolled and randomly assigned to receive either PCV13 
or PCV7 at 3, 5, and 11 months of age subjects, as rec-
ommended by the national pediatric vaccination sched-
ule. The immunogenicity of the vaccines, measured 1 
month after the two-dose primary series and 1 month 
after the toddler dose, was evaluated in terms of anti-
body responses to DTaP-HBV-IPV/Hib antigens, and 
serotype-specific anticapsular polysaccharide IgG re-
sponses and antipneumococcal opsonophagocytic assay 
(OPA), in a subset group of infants, for pneumococcal 
vaccines. The response to DTaP-HBV-IPV/Hib antigens 
was comparable with both PCV13 and PCV7. PCV13 
elicited antipneumococcal capsular IgG antibodies to 
all 13 vaccine serotypes, with marked increases in con-
centrations registered after the toddler dose. Although 
a lower immunogenicity for serotypes 6B and 23F was 
observed after the primary series of PCV13, responses to 
the seven common serotypes were comparable between 
the PCV13 and PCV7 groups when measured after the 
toddler dose. Moreover, PCV13 was able to elicit sub-
stantial levels of OPA activity against all 13 serotypes 
following both the infant series and the toddler dose. In 
conclusion, the results of this phase III clinical trial in-
dicated that PCV13 could be administered as part of a 
routine infant immunization program implemented by a 
2 + 1 schedule [44].
Similar findings have been obtained when PCV13 was 
administered according to a 4-dose series in infants, 
and as a toddler dose in infants previously vaccinated 
with PCV7. In a phase III clinical trial, a total of 613 
healthy subjects aged 2 months were enrolled and ran-
domly assigned to receive either PCV13 or PCV7 at 2, 
3, and 4 months concomitantly with pentavalent vaccine 
containing diphtheria, tetanus, 2-pertussis components, 
inactivated poliovirus, and Hib vaccine antigens. At 12 
months of age (toddler dose), all subjects received the 
toddler dose of pentavalent vaccine and children assigned 
in the PCV13 group received a toddler dose of PCV13 
(PCV13/PCV13 group), whilst half of the subjects in the 
PCV7 group received a toddler dose of PCV7 (PCV7/
PCV7 group), and the other half received one dose of 
PCV13 (PCV7/PCV13 group). Anti-pneumococcal im-
Tab. I. Overview of the 13-valent pneumococcal conjugate vaccine (pCv13) phase 3 clinical development.
Non Inferiority Studies
Evaluation of different dosing schedules
      «3 + 1» schedule 2, 3, 4 & 12-15 months 2, 4, 6 & 12-15 months
      «2 + 1» schedule 2, 4 & 12 months 3, 5 & 11 months
      «3 + 0» schedule 6, 10 & 14 weeks
Older children (never vaccinated): 1, 2 or 3 doses
Transition study (PCV13 following 7-valent pneumococcal conjugate vaccine)
Immune response to concomitantly administered vaccine
hexavalent-, pentavalent-, dtwp-, mmr-, mmrv-, menC-, hav-, 
hBv-vaccines and Opv
Safety evalutation in all studies
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mune responses were studied by measuring serotype-
specific anticapsular polysaccharide IgG antibodies 1 
month after the infant series in PCV13 recipients and be-
fore the toddler dose and 1 month after the toddler dose 
in all subjects. OPA against the 6 additional serotypes 
(1, 3, 5, 6A, 7F, and 19A) were performed, after the tod-
dler dose, in a subset of 100 subjects from the PCV13/
PCV13 and PCV7/PCV13 study groups. Following the 
infant dose series, PCV13 resulted able to elicit similar 
immune response for the 7 serotypes in common to both 
PCV13 and PCV7. For these 7 common serotypes, the 
immunogenicity were comparable across all the study 
groups also after the toddler dose. With respect to the six 
additional serotypes, the immune response elicited by 
the infant doses of PCV13 was similar to that measured 
against the common serotypes. A robust response to the 
6 additional serotypes were also elicited by the toddler 
dose of PCV13 toddler dose both after PCV13 and PCV7 
infant series. The capability of a single toddler dose of 
PCV13 to potentially provide protection against the 6 
additional serotypes is further supported by the observed 
elicitation of functional OPA responses [45].
On the basis of the above mentioned results, PCV13 
vaccination has been implemented since 2010 in several 
countries, according to different vaccinations schedules 
providing recommendations also for the administration 
of PCV13 in children that had already received one or 
more doses of PCV7. In Italy, PCV13 has been initially 
authorized for the active prevention of IPD, pneumonia 
and acute otitis media in infants and children aged be-
tween 6 months and 5 years. According to the Italian vac-
cination schedule (Fig. 1), non-vaccinated infants should 
be received 3 doses of PCV13 at 3, 5 and 12 months 
concomitantly with the three doses of DTaP-HBV-IPV/
Hib vaccine. Non-vaccinated children aged between 12 
and 24 months and above to 24 months, should receive 
Fig. 1. 13-valent pneumococcal conjugate vaccine italian vaccination schedule for healthy in-
fants (a) and infants affecting by risk conditions for invasive pneumococcal disease (b).
two doses of PCV13 at intervals of two months and a 
single dose of vaccine, respectively. Infants and children 
who started immunization with PCV7 may complete it 
by switching to PCV13 at any stage of the vaccination 
schedule [46]. Similar schedules have been adopted also 
in other European countries such as France and UK.
In US, the primary infant series consists of 3 doses of 
PCV13, administered at 2,4 and 6 months at intervals of 
approximately 8 weeks, and the booster dose is recom-
mended at age 12-15 months and at least 8 weeks after 
the third dose. Healthy children aged 7-59 months who 
have not been vaccinated with PCV7 or PCV13 previ-
ously should receive 1 to 3 doses of PCV13, depend-
ing on their age at the time when vaccination begins and 
whether underlying medical conditions are present. In-
fants and children aged < 24 months who have received 
≥ 1 dose of PCV7 should complete the vaccination series 
with PCV13. Children aged 12-23 months who have re-
ceived 3 doses of PCV7 before age 12 months are rec-
ommended to receive 1 dose of PCV13, administered 
at least 8 weeks after the most recent dose of PCV7. Fi-
nally, 1 dose of PCV13 is recommended for all healthy 
children aged 24-59 months with any incomplete PCV 
schedule (PCV7 or PCV13) before age 24 months [37].
Adult vaccination with the pneumococcal 
conjugate vaccines: looking to the future 
with the new generation 13-valent 
conjugate formulation
Sp is responsible for significant morbidity and mortality 
worldwide in adults, related both to IPD and non-IPD. In 
particular, pneumococcal CAP determine a significant 
impact in older adults because of its relatively high inci-
dence rate, the associated economic cost, and their high 
case-fatality rates. However a 
precise estimation of the burden 
of pneumococcal pneumonia is 
challenging since the diagnosis 
of pneumonia can be confused 
with several other common 
infectious and non-infectious 
diseases, including bronchitis, 
congestive heart failure, pulmo-
nary infarction, and atelectasis. 
Furthermore, the etiological 
agent of pneumonia is not iden-
tified for the great majority of 
cases, and thus the proportion 
of all pneumonia cases caused 
by Sp remains uncertain.
Recently, some interesting 
studies have assessed the bur-
den of IPD and pneumococcal 
pneumonia among older adults 
both in US and Europe. Wey-
cker et al. estimated that among 
the 91.5 million US adults aged 
≥ 50 years, 29,500 cases IPD 
(27,700 cases of bacteremia 
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and 1,800 cases of meningitis), 502,600 cases of non-
bacteremic pneumococcal pneumonia (198,600 cases 
requiring hospital care and 304,000 cases treated outside 
the hospital setting), and 25,400 pneumococcal-related 
deaths (6,200 due to invasive disease and 19,200 due to 
pneumonia) are estimated to occur yearly. In terms of di-
rect and indirect costs, this important clinical impact has 
been translated into an annual estimation of 3.7 and 1.8 
billion dollars respectively, most of which (81% direct 
and 62% indirect) are attributable to non-bacteriemic 
pneumococcal pneumonia [47].
The impact of CAPs among older adults has been inves-
tigated also within the European context, where the total 
annual rate ranged between 1.6 and 12/1000, including 
both hospitalized and non-hospitalized cases. A recent 
study, performed in Germany on a large national data-
base including the entire adult population, based on the 
analysis of the hospital discharge chart including diag-
noses for CAP (n = 388,406), showed an annual inci-
dence of this clinical picture equal to 2.75 and 2.96/1000 
inhabitants in 2005 and 2006, respectively. The mean 
incidence of CAP, during the study period, resulted 
7.65/1000 in patients aged > 60 years [48]. 
Moreover, a recent review, analyzing the clinical and 
economic burden, etiology and resistance patterns of 
CAP in European adults, demonstrated that the inci-
dence of CAP varied by country, age and gender, and 
was higher in individuals aged ≥ 65 years and in men; 
related mortality varied from < 1% to 48% and was as-
sociated with advanced age, co-morbidity conditions 
and CAP severity. Sp resulted the most common agent 
isolated [49]. Furthermore, Sp plays an important role in 
determining secondary bacterial pneumonia in case of 
both influenza epidemics and pandemics, representing 
an important cause of excess mortality. The synergism 
between influenza virus and Sp was first suggested by 
studies performed on samples collected during autopsy 
from victims of 1918 influenza pandemic, and has been 
recently confirmed by data collected during the 2009 A/
H1N1v influenza pandemic [50].
The severe burden of Sp among adults together with 
the controversial efficacy of the PPV23, particularly 
in those subject at highest risk for IPD and pneumonia, 
and its immunological inability to adequately stimulate 
the T-cell dependent immune response, resulting in the 
failure to create an immunological memory, has recently 
led to investigate the immunogenicity of pneumococcal 
conjugate vaccines in adults and elderly, when adminis-
tered either as primary or booster dose. 
A pivotal dose-ranging study, performed among 220 
elderly aged 70-79 who had received the PPV23 at least 
5 years prior to enrollment and assigned to receive one 
of four volumes (0.1, 0.5, 1 or 2 ml) of PCV7 or a 0.5 ml 
dose of PPV23, showed that the administration of a 1 ml 
dose of PCV7 vaccine is more immunogenic than 0.5 ml 
of PPV23 vaccine in elderly adults previously vaccinat-
ed with PPV23; the vaccines were comparable safe and 
well tolerated by the study-subjects [51].
Another study compared the immunogenicity of PCV7, 
in terms of antipolysaccharide enzyme-linked immuno-
sorbent assay antibody concentrations and OPA, with 
that of PPV23 within 220 adults aged > 70 years who 
had not been previously vaccinated with a pneumococ-
cal vaccine. One year after the vaccination, the subjects 
vaccinated with PCV7 received a booster dose of either 
PCV7 or PPV23, while all subjects immunized with 
PPV23 received a booster dose of PCV7. The results 
demonstrated that an initial dose of PCV7 was likely 
to elicit higher and potentially more effective levels of 
antipneumococcal antibodies than those measured af-
ter primary immunization with PPV23. Interestingly, 
the initial dose of PCV7 created an immunological re-
sponse that permits subsequent administration of PCV7 
or PPV23 to maintain functional antipolysaccharide an-
tibody levels, while the initial dose of PPV23 induced 
a condition of hyporesponsiveness, thus the successive 
administration of PCV7 induced significantly lower an-
tibacterial responses for all serotypes, compared with 
those induced by PCV7 alone [52]. The antipolysac-
charide enzyme-linked immunosorbent assay antibody 
concentrations against type 6B for the 3 cohorts of sub-
jects, evaluated after both the first and second doses of 
vaccine, are summarized in Figure 2.
More recently, a randomized, double-blind clinical study 
compared the immunogenicity, in terms of OPA titer, 
of a single dose of PCV13 with PPV23 in 835 adults 
aged 60-64 years and the immunogenicity of PCV13 in 
404 adults aged 50-59 years compared to that measured 
within the 60-64 years study group. Among adults 60-64 
years, 1 month following vaccination, OPA titers in the 
PCV13 group resulted significantly higher than in the 
PPV23 group in 8 out of 12 serotypes common to both 
Fig. 2. antipneumococcal polysaccharide binding antibody re-
sponses against streptococcus pneumoniae type 6B, elicited dur-
ing the immunization series (from de roux et al., 2008 [52], mod.).
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vaccines (1, 4, 6B, 7F, 9V, 18C, 19A and 23F) and for 
6A (not contained in the PPV23), while it was compara-
ble for the other 4 common serotypes (3, 5, 14 and 19F). 
With respect to the 50-59 years study group, 1 month 
following vaccination, OPA titers were significantly 
higher than in subjects aged 60-64 years for nine sero-
types and were comparable for the other four serotypes. 
In both age groups OPA titers declined from one month 
to one year after PCV13 administration, but remained 
higher than baseline titers. These results clearly support 
a potential benefit of PCV13 in pneumococcal vaccine 
naïve older adults [53].
A randomized, double-blind study, performed among 
938 adults > 70 years of age, previously vaccinated with 
a single dose of PPV23 at least five years prior to en-
rollment, evaluated the immunogenicity of PCV13 in 
comparison with PPV23. One year after the enrollment 
vaccination (PCV13 or PPV23), all subjects received a 
dose of PCV13. Blood samples were obtained prior to 
and at one month after each vaccination and tested for 
OPA titers. Among enrolled subjects, at 1 month after 
the enrollment vaccination, OPA titers in the PCV13 
group were significantly higher than in the PPV23 group 
in 10 out of 12 serotypes common to both vaccines (1, 4, 
5, 6B, 7F, 9V, 18C, 19A, 19F and 23F) and for 6A (not 
contained in the PPV23), whilst it was comparable for 
the other 2 common serotypes (3 and 14). Furthermore, 
OPA titers increased in response to the PCV13 given at 
one year, but the responses to the dose of PCV13 given 
at one year were generally higher in the group that re-
ceived PCV13 at enrollment compared with the group 
that received PPV23 at enrollment [54].
Since pneumococcal vaccine and seasonal influenza 
vaccine are commonly recommended for older adults, 
the possibility to administer concomitantly both vac-
cines is an important topic to investigate in order to 
facilitate immunization. Compatibility of the PPV23 
co-administered with the influenza vaccine has been 
demonstrated previously. Recently, a randomized, 
double-blind clinical study has evaluated the safety 
and immunogenicity of PCV13 when administered 
concomitantly with the Trivalent inactivated Influenza 
Vaccine (TIV) in adults aged ≥ 65 years who are naïve 
to PPV23. The 1160 enrolled subjects were randomized 
1:1 to receive PCV13+TIV followed by placebo, or 
Placebo+TIV followed by PCV13 at 0 and 1 months. 
Blood samples were drawn at 0, 1, and 2 months and 
tested for serotype-specific anticapsular polysaccha-
ride immunoglobulin G geometric mean concentra-
tions. Slightly lower anticorpal titers were observed 
with PCV13+TIV relative to PCV13, but overall con-
comitant PCV13+TIV demonstrated acceptable immu-
nogenicity and safety compared with either agent given 
alone, thus opening the possibility to co-administer the 
two vaccines [55].
On the basis of these results obtained in the clinical de-
velopment plan of PCV13 when administered in adults 
aged 50 years, the European Medicine Agency, in Sep-
tember 2011, extended the indication to use of PCV 13 
to include active immunization of adults aged ≥ 50 years 
against IPD [56].
The positive results, in terms of immunogenicity, ob-
tained with pneumococcal conjugate vaccines in adults 
need to be confirmed as effectiveness in the prevention 
of IPD and CAP. In this view, a clinical trial, entitled 
“Community Acquired Pneumonia Immunization Trial 
in Adults”, has been performing in order to establish 
the efficacy of PCV13 vaccine in the prevention of a 
first episode of vaccine-serotype specific pneumococcal 
CAP among 85,000 Dutch community-dwelling adult 
persons aged ≥ 65 years [57]. Preliminary results of the 
study should be available soon and the definitive results 
will be critical to determine the position of conjugate 
pneumococcal vaccines in the prevention of pneumo-
coccal disease.
In conclusion, the availability of a new generation of 
conjugate pneumococcal vaccines with an enlarged 
antigenic spectrum (i.e. PCV13), together with the 
excellent results obtained worldwide with PCV7, in 
terms of effectiveness against the different clinical 
forms attributable to Sp, offer promising perspectives 
to improve prevention and control of IPD and non-
IPD, particularly CAP, not only in children, but also 
among adults.
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